G protein-coupled receptors (GPCRs) are the largest family of membrane proteins and are involved in various disease including hypertension and airway diseases. With >30% of the prescription drugs targeting GPCRs, they have immense therapeutic importance. The detection of antibodies against GPCRs in these diseases has been a challenging task due to the lack of efficient detection assays, which are easy to use and economically available. The company Acudex has a long-term interest in the development of GPCR assays for autoimmune diseases. The proposed project is focused on the validation of the detection assays for two GPCRs, Angiotensin II type I receptor (AT1R) and Endothelin type A receptor (ETAR) and identification of the binding site(s) for antibodies on these GPCRs. Validation of the assay will be done by using a known antibody and serum samples from kidney transplanted patients. TO BE CONT’D
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.